Impact of antiviral treatment on survival in HCV-positive liver recipients

Annals of Transplantation

Volumn 19, Issue 1, 2014, Pages 367-372

  Wawrzynowicz Syczewska, Marta ^a   Zeair, Samir ^b   Andruszkiewicz, Anna ^a   Bartoszewicz, Klaudia ^a   Sławiński, Jarosław ^a   Laurans, Łukasz ^a   Jurczyk, Krzysztof ^a   Karpińska, Ewa ^a   Socha, Łukasz ^a   Duczkowska, Marta ^a   Parczewski, Miłosz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Marie Curie Hospital   (Poland)

Author keywords

Chronic hepatitis C; Orthotopic liver transplantation; Reinfection; Survival

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; COHORT ANALYSIS; COMPLICATION; END STAGE LIVER DISEASE; EPIDEMIOLOGY; FEMALE; HEPATITIS C, CHRONIC; HUMAN; KAPLAN MEIER METHOD; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; POLAND; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; END STAGE LIVER DISEASE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLAND; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; YOUNG ADULT;

EID: 84905646020     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.890612     Document Type: Article

References (18)

1. Eurich D, Bahra M, Neuhaus P: HCV-recurrence after liver transplantation. In: Liver Transplantation - Basic Issues. Edited by H. Abdeldayem and N. Allam, Intech 2012, Croatia
2. Wiesner RH, Sorrell M, Villamil F: Report of the frst International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transplantation, 2003; 9: S1-S9
3. Samuel D, Bizollon T, Feray C et al: Interferon alpha 2b plus ribavirin with chronic C after liver transplantation: a randomized study. Gastroenterology, 2003; 124: 642-650
4. Berenguer M, Palau A, Fernandez A et al: Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplantation, 2006; 12: 1067-1076
5. Watashi K, Hijikata M, Hosaka M et al: Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology, 2003; 38: 1282-1288
6. Berenguer M, Aguilera V, Prieto M et al: Efect of calcineurin inhibitors on survival and histologic disease severity on HCV-infected liver transplant recipients. Liver Transplantation, 2006; 12: 762-767
7. Berenguer M: Recurrent hepatitis C: worse outcomes established, interventions still inadequate. Liver Transplantation, 2007; 13: 641-643
8. Harper SJ, Gelson W, Harper IG et al: Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience. Transplantation, 2011; 91: 128-132
9. Fasola CG, Netto GJ, Jennings LW et al: Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplantation Proceedings, 2002; 34: 1563-1564
10. Germani G, Pleguezuelo M, Villamil F et al: Azathioprine in liver transplantation: a reevaluation of its use and comparison with mycophenolate mofetil. Am J Transplant, 2009; 9: 1725-1731
11. Gane EJ, Portman BC, Naoumov NV et al: Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med, 1996; 334: 815-820
12. Boker KHW, Dalley G, Bahr MJ et al: Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology, 1997; 25: 203-210
13. Forman LM, Lewis JD, Berlin JA et al: The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology, 2002; 122: 889-896
14. Tanaka T, Selzner N, Therapondos G et al: Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. Transpl Int, 2013; 26: 42-49
15. Neumann UP, Berg T, Bahra M et al: Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol, 2004; 41: 830-836
16. Xirouchakis E, Triantos C, Manousou P et al: Pegylated-interferon and rib-avirin in liver transplant candidates and recipients with HCV cirrhosis: systemic review and meta-analysis of prospective controlled studies. J Viral Hepat, 2008; 15: 699-709
17. Everson GT, Kulig CC: Antiviral therapy for hepatitis in the setting of liver transplantation. Curr Treat Options Gastroenterol, 2006; 9: 520-529
18. Cicinnati VR, Iacob S, Klein CG et al: Ribavirin with either standard or pe-gylated interferon to treat recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther, 2007; 26: 291-303